Alumis (NasdaqGS:ALMS) 2026 Conference Transcript

Summary of Alumis Conference Call Company Overview - Company: Alumis - Industry: Precision Immunology, specifically focusing on psoriasis and other autoimmune diseases Key Points and Arguments Financial and Operational Highlights - Alumis has a strong balance sheet with over $630 million in cash, providing runway into the fourth quarter of 2027 [91] - The company is preparing for a potential NDA filing in the second half of 2023 [37] Clinical Development - Envudeucitinib: Phase 3 results in psoriasis show: - PASI 75 at week 24 is in the 70s% - PASI 90 and PASI 100 rates are approximately 65% and 40%, respectively [3] - Fast onset of action with separation of PASI scores observed as early as week 4 [3] - Safety profile consistent with Phase II data, with no new safety signals [3] Market Dynamics - The oral drug market for psoriasis is expected to expand significantly, as 75% of psoriasis patients prefer oral medications over injectables or topicals [27] - Current market dynamics indicate that the patient share of oral drugs is higher than that of injectables [25] - Alumis aims to position itself strongly in the oral psoriasis market, particularly for patients with scalp involvement and significant itch [31] Competitive Landscape - The company acknowledges competition from other TYK2 inhibitors, including Sotyktu and Zasocitinib from Takeda [22] - Alumis believes its product has a competitive edge in terms of efficacy and quality of life improvements [18] Future Indications and Research - Alumis is exploring additional indications beyond psoriasis, including Systemic Lupus Erythematosus (SLE) and other autoimmune diseases [46] - The company is conducting a pivotal Phase IIb trial for SLE, with results expected in the third quarter of 2023 [52] - The potential for 20+ indications is being considered, with a focus on optimizing the psoriasis indication and exploring rheumatology-related conditions [70] Strategic Partnerships - While Alumis has the capability to launch its products independently, the company is open to partnerships to optimize its TYK2 franchise across multiple indications [41][43] Conclusion - Alumis is positioned for significant growth in the precision immunology space, with promising clinical data and a strong financial foundation. The company is strategically preparing for market entry while exploring a broad pipeline of indications.